CDMOs offering Upstream Processing with Cell Therapy in Europe
8 matching organizations
Upstream Processing with Cell Therapy in Europe is a frequent shortlist pattern for sponsors evaluating CDMO partners with regional footprint. This page lists organizations that map to all three dimensions so you can move from broad taxonomy browsing to a geography-aware candidate set.
Profiles emphasize fit-first discovery: review scope, regulatory posture, and provenance on each listing rather than treating this page as a single ranked recommendation.
When you need additional filters (indications, claim status, or free-text search), continue to the main search experience and layer criteria on top of this starting point.
- AGC Biologics
Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- Catalent
Leading global CDMO offering end-to-end development and manufacturing for pharma, biotech, and consumer health—spanning oral dose, biologics, cell and gene therapies, clinical supply, and specialty formulations with advanced technologies and worldwide GMP capacity.
- Cell and Gene Therapy Catapult
UK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
- Charles River Cell & Gene Therapy
Integrated CDMO offering discovery through commercial manufacturing for cell and gene therapies, with expertise in viral vectors, cell therapy manufacturing, and regulatory support across North America, Europe, and Asia.
- FUJIFILM Biotechnologies
CDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.
- Lonza Cell & Gene Technologies
Pioneer and world leader CDMO founded in 1897, offering integrated contract development and manufacturing for biologics, cell and gene therapies, and small molecules across five continents with 20,000 colleagues.
- Oxford Biomedica
Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Delivers end-to-end GMP solutions from preclinical through commercial launch, with facilities across UK, US, and Europe.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Markdown mirror: /explore/svc_upstream_processing/mod_cell_therapy/europe.md